With mo­men­tum from FDA OK, SK Bio­phar­ma to breath new life in­to Ko­re­an biotech with $850M IPO — re­port

SK Life Sci­ence’s re­cent suc­cess at the FDA is set­ting its par­ent com­pa­ny nice­ly for a $850 mil­lion IPO in Ko­rea, the Fi­nan­cial Times re­port­ed.

The group — a sub­sidiary of the con­glom­er­ate SK Hold­ings ded­i­cat­ed to drug dis­cov­ery and de­vel­op­ment — filed its pre­lim­i­nary ap­pli­ca­tion to the Ko­rea Ex­change late last month. But the re­cent US ap­proval for epilep­sy drug Xco­pri, or cenoba­mate, raised an­a­lysts’ ex­pec­ta­tions on the amount they can bag.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.